Last10K.com

Respirerx Pharmaceuticals Inc. (RSPI) SEC Filing 10-K Annual report for the fiscal year ending Sunday, December 31, 2017

Respirerx Pharmaceuticals Inc.

CIK: 849636 Ticker: RSPI
Document and Entity Information - USD ($)
12 Months Ended
Dec. 31, 2017
Mar. 31, 2018
Jun. 30, 2017
Document And Entity Information   
Entity Registrant NameRespireRx Pharmaceuticals Inc.  
Entity Central Index Key0000849636  
Document Type10-K  
Document Period End DateDec. 31, 2017  
Amendment Flagfalse  
Current Fiscal Year End Date--12-31  
Entity Filer CategorySmaller Reporting Company  
Entity a Well-known Seasoned IssuerNo  
Entity a Voluntary FilerNo  
Entity's Reporting Status CurrentYes  
Entity Public Float  $ 3,567,000
Entity Common Stock, Shares Outstanding 3,123,332 
Trading SymbolRSPI  
Document Fiscal Period FocusFY  
Document Fiscal Year Focus2017  

View differences made from one year to another to evaluate Respirerx Pharmaceuticals Inc.'s financial trajectory

Compare SEC Filings Year-over-Year (YoY) and Quarter-over-Quarter (QoQ)
Sample 10-K Year-over-Year (YoY) Comparison

Compare this 10-K Annual Report to its predecessor by reading our highlights to see what text and tables were  removed  ,   added    and   changed   by Respirerx Pharmaceuticals Inc..

Continue

Assess how Respirerx Pharmaceuticals Inc.'s management team is paid from their Annual Proxy

Definitive Proxy Statement (Form DEF 14A)
Screenshot example of actual Proxy Statement

Respirerx Pharmaceuticals Inc.'s Definitive Proxy Statement (Form DEF 14A) filed after their 2018 10-K Annual Report includes:

  • Voting Procedures
  • Board Members
  • Executive Team
  • Salaries, Bonuses, Perks
  • Peers / Competitors

Continue

Tools

Financial Statements, Disclosures and Schedules

Inside this 10-K Annual Report

Document And Entity Information
Consolidated Balance Sheets
Consolidated Balance Sheets (parenthetical)
Consolidated Statement Of Stockholders' Deficiency
Consolidated Statement Of Stockholders' Deficiency (parenthetical)
Consolidated Statements Of Cash Flows
Consolidated Statements Of Cash Flows (parenthetical)
Consolidated Statements Of Operations
Consolidated Statements Of Operations (parenthetical)
Business
Business (details Narrative)
Commitments And Contingencies
Commitments And Contingencies (details Narrative)
Commitments And Contingencies (tables)
Commitments And Contingencies - Schedule Of Principal Cash Obligations And Commitments (details)
Income Taxes
Income Taxes (details Narrative)
Income Taxes (tables)
Income Taxes - Reconciliation Of Income Tax Rate Federal Statutory Rate And Effective Tax Rate (details)
Income Taxes - Schedule Of Deferred Tax Assets (details)
Notes Payable
Notes Payable (details Narrative)
Notes Payable (tables)
Notes Payable - Schedule Of Notes Payable (details)
Notes Payable - Summary Of Note Payable To Related Party (details)
Organization And Basis Of Presentation
Organization And Basis Of Presentation (details Narrative)
Related Party Transactions
Related Party Transactions (details Narrative)
Settlement And Payment Agreements
Settlement And Payment Agreements (details Narrative)
Settlement And Payment Agreements (tables)
Settlement And Payment Agreements - Summary Of Result Of The Forgiveness And Nqso Grant Transactions (details)
Stockholders' Deficiency
Stockholders' Deficiency (details Narrative)
Stockholders' Deficiency (tables)
Stockholders' Deficiency - Schedule Of Exercise Prices Of Common Stock Options Outstanding And Exercisable (details)
Stockholders' Deficiency - Schedule Of Exercise Prices Of Common Stock Warrants Outstanding And Exercisable (details)
Stockholders' Deficiency - Schedule Of Stock Options Activity (details)
Stockholders' Deficiency - Schedule Of Warrants Activity (details)
Subsequent Events
Subsequent Events (details Narrative)
Summary Of Significant Accounting Policies
Summary Of Significant Accounting Policies (details Narrative)
Summary Of Significant Accounting Policies (policies)
Summary Of Significant Accounting Policies (tables)
Summary Of Significant Accounting Policies - Schedule Of Antidilutive Securities Excluded From Computation Of Earnings Per Share (details)
Summary Of Significant Accounting Policies - Summary Of Fair Value Of Option Estimated Using Black-scholes Pricing Model With Valuation Assumptions (details)
Summary Of Significant Accounting Policies - Summary Of Fair Value Of Warrants Estimated Using Black-scholes Pricing Model With Valuation Assumptions (details)
Ticker: RSPI
CIK: 849636
Form Type: 10-K Annual Report
Accession Number: 0001493152-18-005325
Submitted to the SEC: Tue Apr 17 2018 4:13:34 PM EST
Accepted by the SEC: Tue Apr 17 2018
Period: Sunday, December 31, 2017
Industry: Pharmaceutical Preparations

External Resources:
Stock Quote
Social Media

Bookmark the Permalink:
https://last10k.com/sec-filings/rspi/0001493152-18-005325.htm